Summary Human beta-cell glucokinase and its liver counterpart displayed a half-saturating concentration of glucose (S0.s) of about 8 mmol/l and a Hill coefficient of 1.7, and were as sensitive to inhibition by the rat liver regulatory protein as the rat liver enzyme. These results indicate that the N-terminal region of glucokinase, which differs among these three enzymes, is not implicated in the recognition of the regulatory protein. They also suggest that the regulatory protein, or a related protein, could modulate the affinity of glucokinase for glucose in beta cells. We have also tested the effect of several mutations, many of which are implicated in maturity onset diabetes of the young. The mutations affected the affinity for glucose and for the regulatory protein to different degrees, indicating that the binding site for these molecules is different. An AsplSSAla mutation, found in the expression plasmid previously thought to encode the wild-type enzyme, increased the affinity for glucose by about 2.5-fold without changing the affinity for the regulatory protein. The mutations that were found to decrease the affinity for the regulatory protein (Asn166Arg, ValZ°3Ala, AsnZ°4Gln, Lys414Ala) clustered in the hinge region of glucokinase and nearby in the large and small domains. These results are in agreement with the concept that part of the binding site for the regulatory protein is situated in the hinge region of this enzyme. [Diabetologia (1996[Diabetologia ( ) 39: 1173[Diabetologia ( -1179 Keywords Glucokinase, hexokinase, glucokinase regulatory protein, MODY, non-insulin-dependent diabetes mellitus.
Mammalian liver contains a protein inhibitor of glucokinase, which acts competitively with respect to glucose [1] [2] . The effect of this regulatory protein is enhanced by fructose 6-phosphate and counteracted by fructose 1-phosphate, both of which act by binding to the inhibitor protein [3] . The regulatory protein inhibits glucokinase by forming a complex with this enzyme; kinetic experiments have suggested that glucokinase has distinct binding sites for the regulatory protein and the substrate analogue N-acetylglucosamine [4] .
The regulatory protein is specific for glucokinase; it is found in the livers of species that express glucokinase and is absent in species in which glucokinase is absent [5] . Its presence in islets is inferred from the observations that glucokinase activity in islet homogenates is slightly increased by fructose 1-phosphate and that islet homogenates inhibit rat liver glucokinase in a fructose 1-phosphate-sensitive manner [6] . Direct demonstration of the presence of the regulatory protein in islet tissue is, however, still lacking. Glucokinase partially purified from islet extracts is sensitive to the rat liver regulatory protein, but the paucity of the enzyme does not permit a detailed kinetic analysis of the effect of the regulatory protein on islet glucokinase [6] . Betacell glucokinase differs from its liver counterpart [7] by the first 15 amino acids encoded by exon 1 or 1' [8] .
The availability of recombinant human beta-cell glucokinase [9] has made it possible to study more carefully the kinetic effects of rat liver regulatory protein. In this report, we have also investigated the sensitivity of various glucokinase mutants, some of which are found in maturity onset diabetes of the young (MODY) [9] [10] [11] [12] [13] , to the regulatory protein to ascertain whether these mutations alter the affinity for glucose to the same extent as the affinity for the regulatory protein. While this work was in progress, it was found that the recombinant clone from which the expression vectors for human islet and human liver glucokinases were derived contained a mutation replacing Asp 158 [14, 15] by an alanine residue. We have also investigated the effect of this mutation.
Materials and methods
The regulatory protein was purified from rat liver up to the hydroxylapatite step [16] and was freed of inorganic phosphate by gel filtration on Sephadex G-25. Rat liver glucokinase was purified from livers as described previously [9] . The preparation of recombinant forms of human liver and human betacell glucokinase (which are actually Asp158Ala mutants), and of the site-directed mutants of the latter enzyme was reported previously [9] [10] [11] [12] . It should be noted that the construction of the Asn~66Arg mutant led to the reversion of Ala I5s to an Asp residue. The true wild-type enzymes were prepared by "repairing" the Ala 158 mutation according to the following site-directed mutagenesis procedure. The 5' (up to nucleotide 480) and the 3' (from nucleotide 48I) coding regions of the human beta-cell glucokinase cDNA inserted in pBlueScript KS + (pBS-HIGKAsp158Ala) were amplified in two separate PCR reactions with Pwo DNA polymerase using as primers T7 and 5' -ATCGATATCTTCGTGCCTCAC -3', for the 5' region and T3 and 5' -AAGGGCATCCTTCTCAACTGG -3', for the 3' region. The glucokinase-specific primers (mismatches underlined) were phosphorylated at their Y-ends. The amplified fragments (560 and 1355 base pairs [bp]) were restricted with Xba I and Barn HI, respectively, and purified by agarose gel electrophoresis. They were then simultaneously ligated in pBS that had been restricted with both XbaI and BamHI, and the resulting construct was used to transform Escherichia coli JM 109. The glucokinase insert was checked by sequencing to exclude polymerase chain reaction (PCR) errors. The expression vector for human wild-type beta-cell glucokinase (pET-HIGKAla158Asp) was then constructed by replacing a SacII-SacI fragment in the expression vector coding for human beta-cell glucokinase Asp~SSAla by the corresponding "repaired" fragment. The expression vector for human wild-type liver glucokinase (pET-HLGKAla]SSAsp) was similarly constructed. These "repaired" cDNAs were subsequently used to transform E. coli BL21(DE3) pLysS [17] and the recombinant proteins were expressed and purified as described [18] .
Glucokinase was assayed spectrophotometrically at 30 
Results
Effect of the regulatory protein on the kinetics of the wild-type enzyme. For the kinetic studies, glucokinase was assayed at pH7.1 and in the presence of 25 mmol/1 KC1. These conditions are optimal to study the effect of the regulatory protein because a higher pH or higher concentration of C1-would antagonize its effect [4] . Figure 1 shows that, as for rat liver glucokinase, the glucose saturation curve of the wildtype human beta-cell glucokinase was sigmoidal, displaying under our assay conditions a S0. 5 of approximately 8 mmol/1 and a Hill coefficient close to 1.7. Figure 1 also shows that rat liver regulatory protein caused an increase in the S0. 5 value without changing Vma x, i.e., that the regulatory protein behaved as a competitive inhibitor. Plots of 1/v as a function of the concentration of inhibitor at different concentrations of glucose were linear and their extrapolations crossed at a value of about -0.8 U of regulatory protein/ml (Fig.2) . Based on these results, it was concluded that the competitive inhibition constant of beta-cell glucokinase was 0.8 U regulatory protein/ml, i. e. 4 nmol/1 [16] . A similar value was obtained with rat liver glucokinase (results not shown).
As previously reported for rat liver glucokinase [1] , the inhibition exerted by the regulatory protein was modulated by fructose 6-phosphate, which increased the inhibition, and by fructose 1-phosphate which antagonized the inhibition (data not shown). Thus, in the presence of 3.2 U of regulatory protein per ml, a half-maximal effect of fructose 6-phosphate was observed at a concentration of about 10 ~tmol/1. At the same concentration of regulatory protein and in the presence of 50 ~tmol/1 fructose 6-phosphate, 20 ~tmol/1 fructose 1-phosphate was needed to release half of the inhibition. KC1 and, to a lesser extent, potassium acetate were found to release the inhibition exerted by the regulatory protein on beta-cell glucokinase (data not shown) with similar sensitivities to those previously observed with rat liver glucokinase [4] . Fig. 3 a, b . Hill plot (a) Hanes plot (b) of the glucose saturation curve of wild type human islet glucokinase. The activity of the human islet glucokinase was determined at different concentrations of glucose under the assay conditions described in Methods. Data are the means of triplicates + SEM. In (b), the regressions shown have been calculated for three sets of glucose concentrations in retool/l: 1)5 to 20, 2)7.5 to 30 and 3) 20 to 50; the KmS derived from these regressions were 17.9 and 5 mmol/1, respectively the sensitivity of the various mutant forms of glucokinase to the inhibition exerted by the regulatory protein. Since some of the mutations alter the affinity for glucose and the regulatory protein behaves as a competitive inhibitor, it was important to determine the affinity for the regulatory protein under comparable conditions, i.e. at similar degrees of glucose saturation. The half-saturating concentrations of glucose were determined graphically on Hill plots, as exemplified in Figure 3 a for the wild-type beta-cell enzyme. It is apparent that this type of plot was linear and that it allowed the safe calculation of the half-saturating concentration of substrate (8 mmol/l) and the Hill coefficient (1.7). Since some authors have analysed glucokinase kinetics by assuming Michaelis-Menten kinetics [9] [10] [11] [12] [13] , we also show the results as Hanes plots (Fig. 3 b) . As expected for a sigmoidal enzyme, this type of plot was curvilinear and different KrnS (from 5 to 17 mmol/1 in the example) could be calculated depending on the set of data points considered. Table 1 lists the S0. 5 values that we observed under our experimental conditions. They differ from the K m values reported previously [9] [10] [11] [12] [13] , but this is most likely due to the fact that the kinetics were previously analysed assuming Michaelis-Menten kinetics. Furthermore, some of the proteins tested in this work and previously [9] [10] [11] [12] are actually double-mutants. For the Lys414Ala and the Cys414Glu mutants we observed that the inclusion of 25 mmol/1 KC1 in the assay markedly decreased the $0. 5 value (from 16 to 2.3 mmol/1 and from 22 to 4.2 mmol/1, respectively), whereas no such effect was observed with the wildtype enzymes.
Affinity of glucokinase mutants for glucose and Nacetyl-glucosamine. It was of interest to determine
The human beta cell and liver enzymes had the same affinities for glucose, the S0. 5 values of the nonmutated forms being almost identical to that of rat liver glucokinase (-8 mmol/1), while the S0. 5 of the enzymes with the Asp158Ala mutation was about 2.5 fold lower. An S0. 5 value of approximately 3.5 mmol/1 was also observed with this mutant under the assay conditions of Lange et al. [19] . The mutant with the lowest affinity for glucose was the The affinity for N-acetylglucosamine was determined by measuring the concentration of the aminosugar required to inhibit glucokinase by 50 % at a concentration of glucose close to the So. 5 value. For the Valt82Met, the Val2°3Ala, the Asn2°4Gln and the Glu279Gln mutants, the decrease in the affinity for glucose was accompanied by a decrease in the affinity for N-acetylglucosamine. Little change in affinity for this inhibitor was however observed with the other mutants, including the Asp15SAla proteins.
Affinity of glucokinase mutants for the regulatory protein and for palmitoylCoA. The sensitivity of the wildtype and mutant glucokinases to inhibition by the regulatory protein was determined both at a fixed glucose concentration (5 mmol/1 glucose) and at a glucose concentration close to the So. 5 value determined under our experimental conditions. The latter is expected to reflect the affinity for the regulatory protein independent of changes in the affinity for glucose. Care was taken to use concentrations of glucokinase lower than the dissociation constant of the glucokinase/regulatory protein complex (3 x 10 -9 mol/1) to avoid overestimation of the inhibition constants [16] . It should be noted that the Asp158Ala mutation did not result in a change in the affinity for the regulatory protein. Four mutations (Asn166Arg, Val2°3Ala, Asn2°4Gln, and Lysal4Ala) caused a significant decrease (> 1.5-fold) in the affinity for the regulatory protein while the VallSZMet mutation slightly increased this affinity. These changes did not always parallel those in the affinity for glucose or N-acetylglucosamine. Indeed the Valt82Ala mutant, which had a decreased affinity for both glucose and Nacetylglucosamine, showed an increased affinity for the regulatory protein, while the Lys414Ala and the The residues in red and yellow correspond to the mutations that respectively decreased or increased the affinity for the regulatory protein. The residues in orange, Glu 51 and Glu 52 and the loop Val ls4 to Asp 158, were previously shown [18] to decrease the affinity of glucokinase for the regulatory protein when replaced by corresponding residues in rat hexokinase I. The glucokinase model is represented using the MOLSCRIPT software [29] and the coordinates of Charles et al. [30] Asn166Arg mutants had an increased affinity for glucose compared to their respective controls, and a decreased affinity for the regulatory protein.
We have also tested the sensitivity of glucokinase to long chain acylCoAs. All mutants, with two exceptions, displayed a sensitivity to palmitoylCoA that was close, or identical, to that expressed by wildtype human glucokinases, which in turn was the same as that of the rat liver enzyme. As shown in Figure 4 , the Lys414Ala and the Glu279Gln mutants displayed a-~ 2.5-fold decrease in the sensitivity to this effector.
Discussion
The mutation Asp15SAla was found in the expression plasmids used in the present study as well as in the cDNA produced by Nishi and co-workers [14] . It is not known at present if this mutation results from a PCR error (part of the complete c D N A produced by Nishi and co-workers was obtained by amplification with Taq polymerase) or from a cloning artifact. The fact that Asp 158 is conserved among glucokinases [18] and that the Ala 158 variant remained unnoticed until now, despite intensive research of mutations in the glucokinase gene, argues against a polymorphism.
The replacement of this residue by an alanine results in a significant increase in the affinity for glucose. This observation is not surprising since Asp ls8 is situated in the hinge region of glucokinase (Fig. 5) close to residues Val 2°3 and Asn 2°4, which, when mutated to alanine and glutamine, respectively, lead to enzymes with a very low affinity for glucose [20] ( Table 1) . Furthermore it was found recently that the replacement of residues Va1154 to Asp 158 by the corresponding residues of rat hexokinase I results in a tenfold decrease in the affinity for glucose [18] .
The S0. 5 value of the AsplSSAla mutant was consistently found in this work to be about 3.5 mmol/1 while the " K i n " values mentioned in the literature for the same enzyme (reported to be the wild-type enzyme) range between 8 + 2 and 6 + 0.4 mmol/l [9] [10] [11] [12] . This inconsistency is not due to differences in the assay conditions but most likely results from the use of inappropriate methods to calculate K m values for glucokinase (the term K m is actually meaningless for a sigmoidal enzyme). It is well known that, for enzymes with sigmoidal saturation curve, double-reciprocal plots are curvilinear. The same is true for Hanes plots, though the latter type of plot may give the wrong impression of linearity at elevated concentrations of substrate. It can be demonstrated, however, that for an enzyme responding to the Hill equation, there is no linear portion in a Hanes plot if h ¢ 1. This is the reason why different K m values are calculated depending on the set of data used (Fig. 3 b) . In contrast, the use of the Hill plot gives S0 5 values which are independent of the chosen data set (Fig. 3 a) . The importance of correctly determining S0 5 values of glucokinase has been recently discussed by Cardenas [211. Previous work performed on xenopus glucokinase indicated that the regulatory protein binds to the tip of the small domain and to the hinge region of this enzyme [18] . Mutations of residues 51 and 52, as well as of residues 141-144 resulted in a remarkable decrease in the affinity for the regulatory protein (Fig. 5) . The results obtained in the present work confirm and extend these conclusions. Thus, the mutations that result in a decrease in the affinity for the regulatory protein cluster in the hinge region (Val2°3Ala, Asn2°4Gln), in close proximity to Glu 51 and Glu 52, and in the nearby regions of the small (Asn166Arg) and the large domain (Lys414Ala; Fig. 5 ). The increase in affinity induced by the Va1182Met mutation could be due to a change in the positioning of the His141-Leu 144 loop, which appears to play an important role in the binding of the regulatory protein [18] . The fact that the beta-cell enzyme and the liver enzyme have the same affinity for the regulatory protein indicates that the fifteen N-terminal amino acids, which are located in the large domain, are remote from the regulatory protein binding site.
By binding to the hinge region, the regulatory protein is likely to interfere with the closure of the catalytic cleft, which appears to be a prerequisite for the phosphoryl transfer reaction occurring between ATP and glucose in hexokinases.
Until now, only two mutants have been found to have a decreased affinity for palmitoylCoA. Both mutations involve residues (Lys 414 and Glu 279) that are in the large domain of the enzyme. These results indicate that the binding site for palmitoylCoA is most likely on the "internal" face of the large domain (Fig.5) . The lack of synergism between palmitoylCoA and the regulatory protein [16] is probably due to the fact their binding sites partially overlap in the hinge region.
A growing body of evidence indicates that glucokinase plays a critical role in the control of insulin secretion by the beta cell. Insulin secretion correlates with glucose metabolism in beta cells and glucokinase appears to be the rate-limiting enzyme of glycolysis in these cells (reviewed in [22] [23] [24] ). In addition, mutations of the glucokinase gene that result in the synthesis of inactive enzyme or enzyme with reduced activity lead to a form of non-insulin-dependent diabetes called MODY, which is characterized by a decreased insulin secretion (reviewed in [25] [26] ). This condition is inherited in an autosomal dominant fashion indicating that a 50 % decrease or even a decrease of smaller magnitude in the activity of glucokinase is sufficient to cause a significant reduction in insulin secretion.
The fact that islet glucokinase is sensitive to the regulatory protein indicates that a similar type of mechanism to that found in liver could operate in islet cells. Equally, since fructose 1-phosphate was found to stimulate the activity of glucokinase in extracts of islets [6, 27] , this indicates that these cells could contain a regulatory protein that is similar or related to that found in liver. Interestingly, low amounts of regulatory protein mRNA were found in rat islets [27] . However, it remains to be seen if the concentration of regulatory protein is sufficient to exert a significant inhibition in vivo.
Sturis and co-workers [28] have shown that, in several subjects with mutations in the glucokinase gene, insulin secretion was reduced compared to that in control subjects but less than predicted from the calculated decrease in glucokinase flux, suggesting that there are compensatory changes. One possibility is upregulation of the glucokinase expression as a result of the increase in the blood glucose level [26] . The second possibility is a decrease in the inhibitory effect of the regulatory protein. The present work shows that this could be the case for the Val2°3Ala mutant, which has a reduced affinity for the regulatory protein. Patients harbouring this mutation were found to have reduced rates of insulin secretion but this reduction was less than predicted by loss of enzymic activity [26] .
